|Event Date/Time: Oct 28, 2008||End Date/Time: Oct 29, 2008|
|Registration Date: Oct 21, 2008|
According to one source, as much as Â¾ of the value of publicly traded companies in the US come from intangible assets. Therefore if intellectual property due diligence is not properly conducted, companies face the risk of loss of reputation, loss of profits, or even ruin.
This conference will provide you with the latest updates on patent practice and reform, conducting a diligence review and highlight the best practices you need to ensure your due diligence strategies are equipped set up to make the most of potential Pharma/Bio transactions.
Don't miss the opportunity to hear from industry leading experts and their advisors.